AstraZeneca Pauses Vaccine Trial for Safety Review
NY Times
SEPTEMBER 8, 2020
The company halted late-stage trials of its coronavirus vaccine because of a serious suspected adverse reaction in a participant.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
NY Times
SEPTEMBER 8, 2020
The company halted late-stage trials of its coronavirus vaccine because of a serious suspected adverse reaction in a participant.
pharmaphorum
JANUARY 18, 2021
Public health authorities in California are seeking a halt on dosing of one lot of Moderna’s COVID-19 vaccine after reports of allergic reactions at one immunisation clinic. The clinic in question switched to another lot of Moderna vaccine after closing for a few hours.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 9, 2020
Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The post FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel appeared first on.
pharmaphorum
SEPTEMBER 10, 2020
The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies. The post Non-vaccine nasal spray could protect against COVID-19 appeared first on.
European Pharmaceutical Review
JANUARY 18, 2023
mRNA-1345 demonstrated vaccine efficacy (VE) of 83.7 percent in Moderna’s mRNA vaccine Phase III trial targeting respiratory syncytial virus (RSV) in older adults. ” Moderna’s mRNA vaccine – mRNA-1345. mRNA-1345 is an investigational RSV vaccine. Moderna launches two new mRNA vaccine programmes.
Pharmaceutical Technology
DECEMBER 7, 2022
Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.
Express Pharma
JUNE 12, 2024
Moderna has announced positive Phase III data for its COVID-19/influenza combination vaccine, mRNA-1083. Stephanie Kurdach, Infectious Disease Analyst at GlobalData, comments, “Moderna’s mRNA-1083 combines the mRNA-1010 seasonal influenza vaccine candidate with the mRNA-1283 next-generation Covid-19 vaccine candidate.
pharmaphorum
MARCH 2, 2021
Zebra Technologies healthcare lead Chris Sullivan discusses the COVID-19 vaccine rollout and how technology can streamline the process to combat new variants. . While the rollout of the COVID-19 vaccine has signified the first signs of light at the end of the tunnel, the reality is that this public health crisis is still far from over.
STAT
SEPTEMBER 7, 2022
Moving forward, the company will expand patient monitoring in the trial to watch for low magnesium levels, which had resulted in a serious adverse reaction in one study participant that led the FDA to suspend testing earlier this year. Food and Drug Administration on changes to the study’s plan , BioPharma Dive writes. Moving
Express Pharma
JUNE 3, 2024
mRESVIA is Moderna’s second approved product and reportedly the only RSV vaccine available in single-dose pre-filled syringes Moderna, announced that the U.S. This approval is also the first time an mRNA vaccine has been approved for a disease other than COVID-19. The primary analysis with 3.7 per cent (95.88 per cent CI 66.0
pharmaphorum
SEPTEMBER 9, 2020
It’s a bleak day in the fight against COVID-19, after the UK banned social gatherings of more than six people to contain growing numbers of new cases and the lead vaccine trial from AstraZeneca was halted because of a safety concern.
pharmaphorum
JUNE 29, 2021
Giving one dose each of AstraZeneca and Pfizer COVID-19 vaccines provides good protection against the SARS-CoV-2 virus, but may be associated with more adverse reactions, according to new clinical trial data. Third AZ dose generates strong variant response.
Pharmaceutical Business Review
SEPTEMBER 2, 2024
The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. Following the EUA, the vaccine is also recommended by the US Centers for Disease Control and Prevention (CDC). Our updated vaccine targets JN.1, 1.” “Our updated vaccine targets JN.1,
Pharmacy Times
JANUARY 4, 2023
Children who experienced COVID-19-induced multisystem inflammatory syndrome did not experience severe adverse reactions following COVID-19 vaccination.
Pharmaceutical Technology
AUGUST 4, 2022
Sinovac Biotech has reported that its Covid-19 vaccine, CoronaVac, obtained approval from the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People's Republic of China for usage in children of the age six months to three years.
European Pharmaceutical Review
JUNE 2, 2023
The new Intracellular Drug Delivery Centre CPI’s Intracellular Drug Delivery Centre will help predict the stability, efficacy, performance and any potential adverse reactions of RNA vaccines and therapeutics. Novel drug delivery systems like LNPs are needed for RNA therapeutic developments.
Pharmaceutical Business Review
NOVEMBER 10, 2023
Administered as a single dose by injection into the muscle, the vaccine has a live, weakened version of the chikungunya virus. It is expected to cause symptoms in individuals who receive the vaccine similar to those experienced by people with the disease. Initially, the vaccine received fast track and breakthrough therapy designations.
Pharmaceutical Technology
NOVEMBER 20, 2022
Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. The vaccine is indicated for active immunisation to prevent the disease.
Pharmaceutical Technology
SEPTEMBER 14, 2022
Novavax and Serum Institute of India (SII) have reported that the former’s Covid-19 vaccine, NVX-CoV2373, has received full product registration from the South African Health Products Regulatory Authority (SAHPRA), with conditions. The vaccine showed efficacy, with an encouraging safety and tolerability profile, in the trials. .
European Pharmaceutical Review
DECEMBER 19, 2022
Treatment and care of patients with high-risk NMIBC, including those with CIS often involves removing the tumour and the use of the BCG vaccine to reduce the risk that the cancer will recur. Few effective treatment options exist for patients who develop BCG-unresponsive disease. Overall, 51 percent of patients achieved a CR.
PharmExec
OCTOBER 3, 2022
New methods for signal detection offer the potential to identify adverse reactions from vaccines and drugs earlier. November 29th 2022 9 am CT |10 am ET | 3 pm BST | 4 pm CET Statistical signal detection is a crucial tool for rapidly identifying potential risks associated with pharmaceutical products.
pharmaphorum
JANUARY 18, 2023
Moderna is looking to make a swift dash to the finish line with its respiratory syncytial virus (RSV) vaccine candidate, based on the same mRNA technology as its COVID-19 shots, with a filing in with the FDA in the first half of this year. The post With filing due soon, Moderna stakes a claim to the RSV vaccine market appeared first on.
pharmaphorum
JULY 5, 2021
vaccine effectiveness rates, reading the latest updates on local infection rates and cautiously deciding whether it’s safe or not to see their friends again. we have found macro, population-wide trends that largely echo those that have been reported by the CDC and vaccine manufacturers themselves.
PharmaShots
FEBRUARY 28, 2023
The signs and symptoms of a potential vaccine injury can vary. Other adverse reactions that could be attributed to a vaccine injury include neurological disorders such as seizures, autoimmune diseases, and allergic reactions. Read on to learn more about vaccine injuries and their symptoms.
pharmaphorum
JANUARY 26, 2023
Moreover, research has shown that genetic testing can reduce adverse reactions to drugs by nearly one third. The combination of advanced long- and short-read genomic sequencing technologies holds great promise for precision oncology, and in the development of mRNA vaccines for certain cancers.
pharmaphorum
SEPTEMBER 14, 2021
The UK government is due to announce a large-scale booster vaccine campaign against COVID-19 for all adults aged 50 and over later today, adding to its plan for third doses for people with weakened immune systems. A third dose of the shot was approved by the MHRA last week.
Amber
SEPTEMBER 12, 2024
If a clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO. Adverse Events: Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular.
Pharmaceutical Technology
MAY 15, 2023
A major strategy for OV development is genetic manipulation to weaken virus pathogenicity, enhance target selectivity, reduce adverse reactions, and/or insert exogenous therapeutic genes into the virus genome. OVs can be attenuated natural viruses or recombinant viruses.
Quality Matters
OCTOBER 13, 2021
In 2007 and 2008, nearly 150 patients died and hundreds more suffered serious adverse reactions after they were treated with heparin, a commonly used blood-thinning drug. Heparin is made from pig intestines, which at that time in China were subject to sharp price increases due to widespread pig deaths from “blue ear disease.”
FADIC
JANUARY 12, 2023
Contraindications: Hypersensitivity reaction to paracetamol or any of the other ingredients. Side effects: Infrequent adverse reactions may include anaphylaxis, skin rash, angioedema, thrombocytopenia, bronchospasm, Stevens-Johnson syndrome, hepatic dysfunction, and toxic epidermal necrolysis. g of sugar.
pharmaphorum
OCTOBER 26, 2020
US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adverse reaction in one patient who received the shot. The post AZ, J&J COVID-19 vaccine trials okay to restart in US appeared first on.
European Pharmaceutical Review
JULY 20, 2022
1 But while data on adverse reactions is rightly used to help with these decisions, there is currently no additional modelling on the positive impact regulatory action could have on public health. Researchers also study the long-term effects of medicines and vaccines, as well as the safety of new and advanced products.
pharmaphorum
MARCH 16, 2021
The decision by around a dozen EU countries to suspend dosing with AstraZeneca’s COVID-19 vaccine is facing criticism, amid fears that it could undermine the response to the pandemic in Europe. . It is a completely one-sided argument, statistically, that we need to be vaccinating,” he said. “I
Pharmaceutical Technology
JULY 6, 2022
The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.
Pharmaceutical Technology
AUGUST 14, 2022
Novavax and its partner SK bioscience have obtained a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), to be used in adolescents of the age 12 to 17 years. It enrolled 2,247 adolescents across 73 US sites.
European Pharmaceutical Review
NOVEMBER 10, 2023
The US Food and Drug Administration (FDA) has approved Valneva SE’s IXCHIQ ® , the first chikungunya vaccine to be authorised in the world. The single-dose, live-attenuated vaccine is indicated for preventing chikungunya virus disease in individuals over 18 years old who are at increased risk of contracting the virus.
RX Note
FEBRUARY 23, 2023
Drug-Food Interactions - Predominantly the effect of food on absorption Drugs and Pregnancy - Discussing FDA Pregnancy and Lactation Final Rule and Australian Categories for Prescribing Medicines in Pregnancy Drugs and Lactation - Discussing key references Dosing in Obese - One dose fits all?
LifeProNow
APRIL 19, 2023
The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA.
pharmaphorum
SEPTEMBER 10, 2020
AstraZeneca’s decision to halt all its phase 3 trials of COVID-19 vaccine AZD1222 after an adverse reaction in a single UK volunteer may end up just being a precautionary, but could still see the shot fall behind vaccines from rival developers.
The Thyroid Pharmacist
NOVEMBER 8, 2024
A new test is being developed for MAP detection in support of a vaccine for Crohn’s disease; it has been in clinical trials, and looks very promising. Researchers found they could suppress the autoimmune response if using a vaccine or antibiotic that specifically eradicates E. In one study, genetically susceptible mice with E.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content